Mon.Jan 13, 2025

article thumbnail

Moderna shares tumble on slashed sales guidance

Bio Pharma Dive

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

Sales 303
article thumbnail

JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic

Pharmaceutical Technology

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

Research 277
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

Bio Pharma Dive

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

Drugs 248
article thumbnail

Eli Lilly targets Scorpion Therapeutics to expand reach in oncology

Pharmaceutical Technology

After selling its PI3K program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotechs current shareholders.

147
147
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Lilly pads cancer drug pipeline with Scorpion deal

Bio Pharma Dive

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.

Drugs 174
article thumbnail

Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025

Pharmaceutical Technology

CEO Albert Bourla expressed modest optimism for Pfizers 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

147
147

More Trending

article thumbnail

Biogen proposes acquisition of partner Sage Therapeutics

Pharmaceutical Technology

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvaes launch in postpartum depression.

147
147
article thumbnail

Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street

Bio Pharma Dive

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's also unlikely to appease broader investor concerns.

Drugs 158
article thumbnail

Gilead and LEO Pharma link on programmes for inflammatory conditions

Pharmaceutical Technology

Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latters STAT6 programmes.

147
147
article thumbnail

January 13, 2024: STEP-2 Trial of Cervical Cancer Screening Interventions Joins the NIH Collaboratory

Rethinking Clinical Trials

From left to right: Dr. Rachel Winer, Dr. Amanda Petrik, and Dr. Jasmin Tiro, principal investigators of the STEP-2 trial The NIH Pragmatic Trials Collaboratory is pleased to welcome the STEP-2 trial (Self-Testing for Cervical Cancer in Priority Populations) to its portfolio of innovative NIH Collaboratory Trials. Only half of eligible patients in US federally qualified health centers were screened for cervical cancer in 2021.

Trials 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

JP Morgan 2025: GSK acquires IDRx in $1.15bn deal 

Pharmaceutical Technology

IDRxs lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Trials 147
article thumbnail

Lack of regulatory harmonization and other challenges facing clinical services organizations in the APAC market

Bio Pharma Dive

How clinical services organizations are overcoming challenges in the APAC market.

Marketing 130
article thumbnail

Johnson & Johnson in talks to acquire Intra-Cellular Therapies

Pharmaceutical Technology

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

147
147
article thumbnail

Gilead and LEO Pharma partner to develop oral STAT6 program

Pharma Times

Companies aim to provide new treatments for inflammatory conditions

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

The promising future of regenerative medicine

Pharmaceutical Technology

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Medicine 147
article thumbnail

AI set to revolutionise pharmaceutical R&D says GlobalData

Pharma Times

Survey finds AI to enhance productivity and cut costs in the next 12 months

article thumbnail

Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment

Pharmaceutical Technology

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.

Licensing 147
article thumbnail

GSK confirms plan to buy cancer firm IDRx for $1bn

pharmaphorum

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

103
103
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Small matter, big challenges: Nano milling in a sterilised environment 

Pharmaceutical Technology

Nano milling is a vital technique for developing fine particle-sized drug formulations and improving bioavailability of water-soluble APIs.

article thumbnail

Roche’s VENTANA Assay for B-Cell Lymphoma Gets FDA Clearance

XTalks

Roche has announced the FDA clearance of its VENTANA Kappa and Lambda Dual in-situ hybridisation (ISH) mRNA Probe Cocktail assay, which is designed to aid in diagnosing B-cell lymphoma, a cancer that develops in white blood cells specifically B lymphocytes or B cells of the immune system. The test, the first of its kind, offers a highly sensitive method to differentiate between a B-cell malignancy and a reactive immune response.

article thumbnail

Nine-month-old obesity player Metsera files an IPO

pharmaphorum

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

article thumbnail

Gilead and LEO Pharma partner to develop oral STAT6 program

Pharma Times

Companies aim to provide new treatments for inflammatory conditions

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Regeneron, Illumina join $320m Truveta investment

pharmaphorum

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations.

article thumbnail

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

pharmaphorum

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

69
article thumbnail

J&J Inks $14.6 Billion Intra-Cellular Therapies Deal

Pharmaceutical Commerce

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

pharmaphorum

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

article thumbnail

Pharma Pulse 1/13/25: Additional Security Measures for J.P. Morgan Healthcare Conference, Health Plans Under Pressure & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

59
article thumbnail

How data science and AI will transform life sciences in 2025

pharmaphorum

Discover how data science and AI are set to revolutionise the life sciences industry by 2025, with a focus on mRNA technology and CRISPR gene editing. Stay ahead of the curve with these cutting-edge advancements.

article thumbnail

Making Sample Ordering Simpler for HCPs

Pharmaceutical Commerce

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.

59
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.